Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,237,000	$ 2,400,000
Accounts receivable, net of allowance for doubtful accounts of $426,000 ($419,000 at December 31, 2018)	1,994,000	1,509,000
Inventories, net of reserves of $344,000 ($258,000 at December 31, 2018)	4,309,000	4,493,000
Prepaid expenses and other current assets	313,000	224,000
Total current assets	8,853,000	8,626,000
Restricted cash	1,000,000	1,000,000
Equipment and leasehold improvements, net	2,443,000	2,562,000
Right-of-use operating lease assets, net	941,000
Goodwill	781,000	781,000
Intangible assets, net	1,561,000	1,591,000
Other assets	51,000	51,000
Total assets	15,630,000	14,611,000
Current liabilities:
Accounts payable	2,464,000	2,423,000
Accrued payroll and related expenses	470,000	703,000
Deferred revenue	764,000	485,000
Interest payable – related party	461,000	1,513,000
Other current liabilities	1,448,000	1,241,000
Total current liabilities	5,607,000	6,365,000
Convertible promissory note – related party, less debt discount of $6,953,000 ($6,026,000 at December 31, 2018)	1,760,000	1,174,000
Note payable	800,000
Derivative obligations	1,000	1,000
Long term operating lease obligations	854,000
Other non-current liabilities	329,000	340,000
Total liabilities	9,351,000	7,880,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding
Common stock, $0.001 par value; 350,000,000 shares authorized; 22,149,147 issued and outstanding (21,649,147 at December 31, 2018)	22,000	22,000
Paid in capital in excess of par	234,624,000	235,868,000
Accumulated deficit	(229,306,000)	(227,435,000)
Accumulated other comprehensive loss	(17,000)	(13,000)
Total Cesca Therapeutics Inc. stockholders’ equity	5,323,000	8,442,000
Noncontrolling interests	956,000	(1,711,000)
Total equity	6,279,000	6,731,000
Total liabilities and stockholders’ equity	$ 15,630,000	$ 14,611,000